

Thalomid (thalidomide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID NUM	MBER:		
MALE FEMALE HEIC IF YOU ARE NOT THE PATIENT OR THE PRESCR FOLLOWING LINK: HTTPS://MAGELLANRX.COI	IBER, YOU WILL NEED TO SUBMIT A PHI DISC	LOSURE AUTHORIZATION FORM WITH 1	THIS REQUEST WHICH CAN BE FOUND AT THE
PATIENT'S AUTHORIZED REPF AUTHORIZED REPRESENTATIV			
PRESCRIBER INFORMATION			
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:		-1	
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
		•	
MEDICATION OR MEDICAL I	DISPENSING INFORMATION		
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
NEW THERAPY DURATION OF THERAPY (SPECIFIC DATES):		IF RENEWAL: DATE THERAPY INITIATED:	
Continued on next page.			





Thalomid (thalidomide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 □ Cutaneous lupus □ Erythema nodosum leprosum (ENL) □ Gastrointestinal vascular malformation (Weber-Rendu syndrome) □ Multiple myeloma/plasmacytoma □ Myelofibrosis □ Other diagnosis: 				
	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
PRIOR AUTHORIZATION.				
For <u>all diagnoses</u> , answer the following:				
Is the prescriber enrolled in the Thalo	mid REMS program? □ Yes □ No			
For <u>cutaneous lupus</u> , also answer the Is the prescriber a dermatologist? Yes	_			
Has the patient had a previous trial wind quinacrine?* □ Yes □ No *Please provide documentation.	ith an antimalarial medication such as h	nydroxychloroquine, chloroquine, or		
answer the following:	ation (Gastrointestinal angiodysplasia, C			
Does the patient have recurrent or ref	fractory bleeding due to vascular malfor	rmation(s)? Yes No		
Reauthorization: If this is a reauthorization request, and Does patient have chart notes document *Please submit chart notes document	enting a positive clinical response over	the past 12 months?*□ Yes □ No		
For multiple myeloma/plasmacytoma Select Thalomid's use below: Induction therapy Maintenance therapy	, also answer the following:			
_	ill Thalomid be used in combination wit utrophil count (ANC) of at least 1,000 ce			

© 2017 – 2018, Magellan Rx Management, LLC. All Rights Reserved.

Revision Date: 08/22/2018 CAT0252







Thalomid (thalidomide) Prior Authorization Request Form



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Does the patient have a platelet count of at least 30,000/mm3? ☐ Yes ☐ No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

